IOB - Delayed Quote HUF
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muk?do Rt. (0QFP.IL)
At close: October 18 at 4:45 PM GMT+1
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
805,158,000.00
802,755,000.00
630,595,000.00
566,776,000.00
507,794,000.00
Cost of Revenue
283,834,000.00
342,291,000.00
281,322,000.00
248,006,000.00
230,015,000.00
Gross Profit
521,324,000.00
460,464,000.00
349,273,000.00
318,770,000.00
277,779,000.00
Operating Expense
331,507,000.00
308,473,000.00
213,759,000.00
205,010,000.00
194,141,000.00
Operating Income
189,817,000.00
151,991,000.00
135,514,000.00
113,760,000.00
83,638,000.00
Net Non Operating Interest Income Expense
10,755,000.00
-10,449,000.00
6,056,000.00
-999,000.00
185,000.00
Pretax Income
171,540,000.00
165,663,000.00
146,575,000.00
115,164,000.00
50,848,000.00
Tax Provision
10,889,000.00
-5,087,000.00
5,395,000.00
9,112,000.00
2,418,000.00
Net Income Common Stockholders
158,850,000.00
169,076,000.00
139,626,000.00
104,683,000.00
47,135,000.00
Diluted NI Available to Com Stockholders
158,850,000.00
169,076,000.00
139,626,000.00
104,683,000.00
47,135,000.00
Basic EPS
687.00
907.00
751.00
563.00
253.00
Diluted EPS
687.00
907.00
751.00
563.00
253.00
Basic Average Shares
185,653.52
186,333.00
186,008.00
185,971.00
186,011.00
Diluted Average Shares
185,653.52
186,333.00
186,008.00
185,971.00
186,011.00
Total Operating Income as Reported
189,364,000.00
153,555,000.00
135,832,000.00
115,089,000.00
39,896,000.00
Total Expenses
615,341,000.00
650,764,000.00
495,081,000.00
453,016,000.00
424,156,000.00
Net Income from Continuing & Discontinued Operation
158,850,000.00
169,076,000.00
139,626,000.00
104,683,000.00
47,135,000.00
Normalized Income
148,950,024.94
180,657,570.00
141,171,924.61
105,766,096.00
46,134,448.00
Interest Income
24,844,000.00
13,418,000.00
2,950,000.00
915,000.00
914,000.00
Interest Expense
15,340,000.00
8,030,000.00
663,000.00
631,000.00
595,000.00
Net Interest Income
10,755,000.00
-10,449,000.00
6,056,000.00
-999,000.00
185,000.00
EBIT
186,880,000.00
173,693,000.00
147,238,000.00
115,795,000.00
51,443,000.00
EBITDA
237,688,000.00
222,262,000.00
192,160,000.00
155,641,000.00
90,763,000.00
Reconciled Cost of Revenue
283,834,000.00
342,291,000.00
281,322,000.00
248,006,000.00
230,015,000.00
Reconciled Depreciation
50,808,000.00
48,569,000.00
44,922,000.00
39,846,000.00
39,320,000.00
Net Income from Continuing Operation Net Minority Interest
158,850,000.00
169,076,000.00
139,626,000.00
104,683,000.00
47,135,000.00
Total Unusual Items Excluding Goodwill
10,571,000.00
-12,727,000.00
-1,605,000.00
-1,176,000.00
1,051,000.00
Total Unusual Items
10,571,000.00
-12,727,000.00
-1,605,000.00
-1,176,000.00
1,051,000.00
Normalized EBITDA
227,117,000.00
234,989,000.00
193,765,000.00
156,817,000.00
89,712,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
671,024.94
-1,145,430.00
-59,075.39
-92,904.00
50,448.00
12/31/2019 - 10/29/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
AIDA Aida Pharmaceuticals, Inc.
0.0002
0.00%
2HQ.SG Tilray Brands Inc
1.5720
+8.23%
GBLP Global Pharmatech, Inc.
0.3500
0.00%
GSAC GelStat Corp.
0.0003
0.00%
CHHE China Health Industries Holdings, Inc.
0.3300
0.00%
IVX.AX Invion Limited
0.0020
0.00%
ALRPD.PA Rapid Nutrition PLC
0.0392
-2.00%
AAREYDRUGS.NS Aarey Drugs & Pharmaceuticals Limited
61.28
-3.36%
AGY.L Allergy Therapeutics plc
4.8800
-2.40%
MRK.DE Merck KGaA
161.90
+0.09%